In a patient with an ovarian mass, how should serum carcinoembryonic antigen (CEA) and cancer antigen 125 (CA‑125) be measured and interpreted?

CEA and CA-125 Measurement in Ovarian Mass Evaluation

In patients with an ovarian mass, CA-125 should be measured routinely, while CEA (along with CA 19-9) should be measured specifically when mucinous carcinoma is suspected to distinguish primary ovarian tumors from gastrointestinal metastases. 1

When to Measure Each Marker

CA-125: Universal Measurement

• Measure in all patients with suspected epithelial ovarian cancer as part of standard workup 1
• Elevated in ~85% of advanced disease cases 1
• Less useful in early-stage disease (elevated in only ~50% of FIGO stage I cases) 1

Important caveat: CA-125 lacks specificity and can be elevated in:

• Benign conditions: endometriosis, ovarian cysts 1
• Non-gynecological malignancies 1
• Pregnancy, pelvic inflammatory disease 2
• Pancreatic cancer, cirrhosis 2

CEA and CA 19-9: Selective Measurement

Measure specifically when mucinous carcinoma is suspected 1

The critical diagnostic algorithm:

1. If imaging suggests mucinous features, measure CEA and CA 19-9 in addition to CA-125
2. Calculate the CA-125/CEA ratio
3. If ratio is <25:1, strongly consider gastrointestinal primary with ovarian metastasis 1
4. Proceed with endoscopy (upper and lower) if either CEA or CA 19-9 is elevated 1

Interpretation Framework

For Distinguishing Ovarian vs. GI Primary

The CA-125/CEA ratio is the key discriminator 2:

• Ratio >25:1: Suggests primary ovarian malignancy
• Ratio <25:1: Suggests gastrointestinal metastasis to ovary 1

Evidence strength: Multiple studies confirm this ratio optimizes specificity for ovarian versus gastrointestinal primary neoplasms 2. The 2023 ESMO guidelines specifically recommend this threshold 1.

For Mucinous Tumors Specifically

CEA is particularly important for mucinous ovarian carcinomas:

• Only 6 of 17 mucinous ovarian carcinomas are detected by CA-125 alone 3
• CEA is elevated (>5.0 μg/L) in 15 of 17 patients with mucinous ovarian cancer 3
• Best CEA cutoff: 2.33 ng/mL (sensitivity 73.1%, specificity 78.3%) 4
• Best CA-125/CEA ratio cutoff: 11.92 (sensitivity 82.3%, specificity 60.9%) for distinguishing ovarian neoplasms from metastases 4

Clinical Algorithm

Step 1: Measure CA-125 in all patients with ovarian mass

Step 2: Assess imaging characteristics

• If mucinous features present → Add CEA and CA 19-9

Step 3: Calculate CA-125/CEA ratio if both measured

• Ratio <25:1 → Perform endoscopy to rule out GI primary
• Ratio >25:1 → Likely primary ovarian tumor

Step 4: Proceed with appropriate surgical planning based on suspected primary site

Common Pitfalls to Avoid

1. Don't rely on CA-125 alone for mucinous tumors - it misses the majority of cases 3

2. Don't skip endoscopy when indicated - up to 11.6% of apparent ovarian masses are actually metastases 4, and missing a GI primary significantly alters treatment approach and prognosis

3. Don't use CA-125 for screening - insufficient sensitivity in early disease (only 50% in stage I) 1, 2

4. Don't interpret elevated CA-125 in isolation in premenopausal women - high false-positive rate due to endometriosis, functional cysts 2

5. Remember that ultrasound morphology outperforms tumor markers - IOTA models are superior to CA-125 alone for distinguishing benign from malignant masses 1